Efficacy of enrofloxacin and marbofloxacin on bacteria isolated from dogs and cats - in vitro data of antibiotic resistance

Since fluoroquinolones have been licensed for veterinary medicine the development of bacterial resistance has been monitored closely, the more so as their relevance for human medicine is under discussion. Most studies focus on bacteria from food-producing animals whereas there are only relatively few data concerning bacterial strains from companion animals. The present study in which an exceptional high number of 7,118 bacterial strains isolated from dogs and cats were tested provides a survey on the current situation of resistance in small animal medicine. Two of the fluoroquinolones - enrofloxacin (e.g. Baytril (R)) and marbofloxacin (e.g. Marbocyl (R)) - were compared and the results related to Current monitoring data. in comparison enrofloxacin showed equal or even slightly higher in vitro activity than marbofloxacin with exception of Pseudomonas aeruginosa. Potential advantages of enrofloxacin for the in vivo treatment of this difficult pathogen are discussed. The results of the present Study suggest that fluoroquinolone-resistance is Currently noncritical even though it should be carefully monitored. Nevertheless, to secure a long-term high therapeutic value of this important antibiotic group, it is important to adhere to current prudent-use guidelines.